Next Article in Journal
Comminution of Dry Lignocellulosic Biomass: Part II. Technologies, Improvement of Milling Performances, and Security Issues
Next Article in Special Issue
Gelatin-Methacryloyl (GelMA) Hydrogels with Defined Degree of Functionalization as a Versatile Toolkit for 3D Cell Culture and Extrusion Bioprinting
Previous Article in Journal / Special Issue
Dynamic Cultivation of Mesenchymal Stem Cell Aggregates
Review

Towards Multi-Organoid Systems for Drug Screening Applications

1
iBB-Institute for Bioengineering and Biosciences and Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal
2
The Discoveries Centre for Regenerative and Precision Medicine, Lisbon Campus, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal
*
Author to whom correspondence should be addressed.
Bioengineering 2018, 5(3), 49; https://doi.org/10.3390/bioengineering5030049
Received: 14 May 2018 / Revised: 15 June 2018 / Accepted: 19 June 2018 / Published: 21 June 2018
(This article belongs to the Special Issue Advanced Dynamic Cell and Tissue Culture)
A low percentage of novel drug candidates succeed and reach the end of the drug discovery pipeline, mainly due to poor initial screening and assessment of the effects of the drug and its metabolites over various tissues in the human body. For that, emerging technologies involving the production of organoids from human pluripotent stem cells (hPSCs) and the use of organ-on-a-chip devices are showing great promise for developing a more reliable, rapid and cost-effective drug discovery process when compared with the current use of animal models. In particular, the possibility of virtually obtaining any type of cell within the human body, in combination with the ability to create patient-specific tissues using human induced pluripotent stem cells (hiPSCs), broadens the horizons in the fields of drug discovery and personalized medicine. In this review, we address the current progress and challenges related to the process of obtaining organoids from different cell lineages emerging from hPSCs, as well as how to create devices that will allow a precise examination of the in vitro effects generated by potential drugs in different organ systems. View Full-Text
Keywords: human pluripotent stem cells; organoids; body-on-a-chip; multi-organ systems; drug discovery; personalized medicine human pluripotent stem cells; organoids; body-on-a-chip; multi-organ systems; drug discovery; personalized medicine
Show Figures

Figure 1

MDPI and ACS Style

Miranda, C.C.; Fernandes, T.G.; Diogo, M.M.; Cabral, J.M.S. Towards Multi-Organoid Systems for Drug Screening Applications. Bioengineering 2018, 5, 49. https://doi.org/10.3390/bioengineering5030049

AMA Style

Miranda CC, Fernandes TG, Diogo MM, Cabral JMS. Towards Multi-Organoid Systems for Drug Screening Applications. Bioengineering. 2018; 5(3):49. https://doi.org/10.3390/bioengineering5030049

Chicago/Turabian Style

Miranda, Cláudia C.; Fernandes, Tiago G.; Diogo, Maria M.; Cabral, Joaquim M.S. 2018. "Towards Multi-Organoid Systems for Drug Screening Applications" Bioengineering 5, no. 3: 49. https://doi.org/10.3390/bioengineering5030049

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop